EP08.01-067 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC

PD-1 inhibitors are an integral part of treatment in metastatic (m)NSCLC. Immune-related adverse events (irAE) are reported to occur in approximately 30% of patients. However, rates of irAEs in real-world populations are incompletely characterized. Furthermore, there is a paucity of data on PD-1 inhibitor rechallenge and long-term survival benefit specific to NSCLC patients.